The Pharmacy Times® Depression Resource Center is a comprehensive resource for clinical news and expert insights on treatments for the different forms of depression and its symptoms.
June 11th 2025
The authors wrote that a life course approach to the treatment and prevention of depression may help reduce individual burdens of dementia.
Zuranolone Offers An Innovative Treatment for Postpartum Depression
Zuranolone enhances health care providers’ ability to address the complex needs of patients with PPD, offering new hope for rapid and sustained relief from depressive symptoms.
Read More
St. John’s Wort Could Show Benefit in Major Depressive Disorder
Patients with MDD may also seek complementary or alternative therapies in the form of dietary supplements which might be perceived by patients to be natural and safer than medicinal agents.
Read More
Brexanolone and Zuranolone for the Treatment of Postpartum Depression
July 9th 2024The American College of Clinical Gynecology recommends consideration of brexanolone or zuranolone in postpartum patients with onset of moderate-to-severe perinatal depression in the third trimester or within 4 weeks postpartum.
Read More
Understanding Depression: Risk Factors and Evolving Treatments
June 13th 2024At ASHP Pharmacy Futures 2024, Mei T. Liu, PharmD, BCPP, highlights the global prevalence and multifaceted nature of depression, its bidirectional relationship with medical conditions, and the need for diverse, evidence-based treatment options.
Read More
Researchers Find Shared Multiomic Molecular Dysregulations in Brains With PTSD and MDD
June 5th 2024The investigators are optimistic that the data can establish stress-related pathways while revealing potential therapeutic options for patients with major depressive disorder and post-traumatic stress disorder.
Read More